Filtered By:
Source: Neurology
Drug: Coumadin

This page shows you your search results in order of date. This is page number 4.

Order by Relevance | Date

Total 64 results found since Jan 2013.

Use of Apixaban and Warfarin in Patients Undergoing Procedures: Insights from ARISTOTLE (P5.002)
CONCLUSIONS: Procedures are common in patients with atrial fibrillation. The majority of procedures are non-major and non-emergent, and anticoagulation therapy is likely to be stopped peri-procedure. Overall and among emergent procedures, rates of clinical events in the first 30 days post-procedure were low and comparable between treatment groups.Study Supported by: Bristol-Myers Squibb Company and Pfizer Inc. Editorial assistance (i.e., formatting the abstract to ensure compliance with AAN guidelines) was provided by Claire Hall of Caudex Medical and was funded by Bristol-Myers Squibb Company and Pfizer Inc.Disclosure: Dr...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Lopes, R., Garcia, D., Wojdyla, D., Dorian, P., Alexander, J., Wallentin, L., Lanas, F., Hanna, M., Held, C., Granger, C. Tags: Cerebrovascular Disease and Interventional Neurology II Source Type: research

Effect of Apixaban on All-Cause Mortality in Atrial Fibrillation: An Imputed Placebo Analysis (P5.003)
CONCLUSIONS: This imputed placebo analysis suggests that apixaban significantly reduces all-cause mortality by about one-third in patients with AF.Study Supported by: Bristol-Myers Squibb Company and Pfizer Inc. Editorial assistance in formatting the abstract to ensure compliance with AAN guidelines was provided by Stephanie Finucane of Caudex Medical and was funded by Bristol-Myers Squibb Company and Pfizer Inc.Disclosure: Dr. McMurray has nothing to disclose. Dr. Hart has received personal compensation for activities with Sanofi-Aventis Pharmaceuticals Inc., and Bristol-Myers Squibb Co. Dr. Flaker has received personal c...
Source: Neurology - April 9, 2014 Category: Neurology Authors: McMurray, J., Hart, R., Flaker, G., Lopes, R., Wang, J., Hanna, M., Alexander, J., Granger, C., Wallentin, L. Tags: Cerebrovascular Disease and Interventional Neurology II Source Type: research

Strategy to a 5 Minute Door to Needle Time (S5.005)
CONCLUSIONS:Our experience suggests that the "Target: Stroke" strategies (EMS initiation of stroke codes, rapid triage, rt-PA before labs), SMART criteria, and three question tool to predict abnormal coagulation can significantly reduce the time to thrombolysis. However, a multi-disciplinary team, educated and dedicated to providing rapid ischemic stroke treatment, and the development of a culture in which faster treatment is a goal, is a factor that’s impact cannot be measured.Study Supported by:Disclosure: Dr. Parker has nothing to disclose. Dr. Swanson-Devlin has nothing to disclose. Dr. Jahnel has received person...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Parker, S., Swanson-Devlin, T., Jahnel, J., McNeil, C., Talkad, A., Beck, J., Nair, D., Wang, D. Tags: Cerebrovascular Disease and Interventional Neurology: Pre-hospital, Telemedicine, and Related Topics Source Type: research

Treatment Trends In Management Of Intracranial Stenosis In The Pre- And Post-Sammpris Era (I8-1.008)
DISCUSSION: SAMMPRIS had a major impact on treatment trends of physicians managing patients with intracranial stenosis. In the Post-SAMMPRIS survey, 91% of respondents participating in SAMMPRIS and 82% of overall respondents indicated that the SAMMPRIS results changed the way they managed patients with ICAS.As aggressive medical management coupled with optimal risk factor reduction shows promise in reducing rates of recurrent stroke, a novel endovascular therapy will have to seek newer heights of increasing RRR to gain acceptance by practitioners.Disclosure: Dr. Pawar has nothing to disclose. Dr. Turan has received persona...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Pawar, S., Turan, T., Cotsonis, G., Lynn, M., Wooley, R., Stern, B., Derdeyn, C., Fiorella, D., Chimowitz, M. Tags: Clinical Decision Making After the Dust Settles on Clinical Trials Poster Presentations Source Type: research

Warfarin Associated Intracerebral Hemorrhage in Hong Kong Chinese (P7.142)
CONCLUSIONS: WICH is a serious complication of warfarin therapy with high mortality and morbidity. Initial ICH volume, presence of intraventricular hemorrhage and neurological deterioration are independent predictors of clinical outcome.Disclosure: Dr. Teo has nothing to disclose. Dr. Mahboobani has nothing to disclose. Dr. Lee has nothing to disclose. Dr. Siu has nothing to disclose. Dr. Cheung has nothing to disclose. Dr. Ho has nothing to disclose. Dr. Lau has nothing to disclose. Dr. Chan has nothing to disclose.
Source: Neurology - April 9, 2014 Category: Neurology Authors: Teo, K. C., Mahboobani, N. R., Lee, R., Siu, D. C., Cheung, R., Ho, S. L., Lau, G. K., Chan, K. H. Tags: Cerebrovascular Disease and Interventional Neurology: Intracerebral Hemorrhage Outcome and Mortality Source Type: research

Dabigatran -The Future Of Cortical Venous Thrombosis Therapy -A Case Series Study (P6.025)
ConclusionsAs these cases demonstrate, Dabigatran appears be effective and safe in the treatment of single cortical venous sinus thrombosis . However large scale randomized controlled trials will be required to confirm its efficacy as a therapeutic modality .Disclosure: Dr. Mathew has nothing to disclose. Dr. Alexander has nothing to disclose. Dr. Sarma has nothing to disclose. Dr. Nadig has nothing to disclose.
Source: Neurology - April 9, 2014 Category: Neurology Authors: Mathew, T., Alexander, L., Sarma, G., Nadig, R. Tags: General Neurology VI Source Type: research

Effect of Apixaban on All-Cause Mortality in Atrial Fibrillation: An Imputed Placebo Analysis (I2-1.001)
CONCLUSIONS: This imputed placebo analysis suggests that apixaban significantly reduces all-cause mortality by about one-third in patients with AF.Study Supported by: Bristol-Myers Squibb Company and Pfizer Inc. Editorial assistance in formatting the abstract to ensure compliance with AAN guidelines was provided by Stephanie Finucane of Caudex Medical and was funded by Bristol-Myers Squibb Company and Pfizer Inc.Disclosure: Dr. McMurray has nothing to disclose. Dr. Hart has received personal compensation for activities with Sanofi-Aventis Pharmaceuticals Inc., and Bristol-Myers Squibb Co. Dr. Flaker has received personal c...
Source: Neurology - April 9, 2014 Category: Neurology Authors: McMurray, J., Hart, R., Flaker, G., Lopes, R., Wang, J., Hanna, M., Alexander, J., Granger, C., Wallentin, L. Tags: New Antithrombotic Agents for Stroke Prevention Poster Presentations Source Type: research

Warfarin Associated Intracerebral Hemorrhage in Hong Kong Chinese (I2-1.009)
CONCLUSIONS: WICH is a serious complication of warfarin therapy with high mortality and morbidity. Initial ICH volume, presence of intraventricular hemorrhage and neurological deterioration are independent predictors of clinical outcome.Disclosure: Dr. Teo has nothing to disclose. Dr. Mahboobani has nothing to disclose. Dr. Lee has nothing to disclose. Dr. Siu has nothing to disclose. Dr. Cheung has nothing to disclose. Dr. Ho has nothing to disclose. Dr. Lau has nothing to disclose. Dr. Chan has nothing to disclose.
Source: Neurology - April 9, 2014 Category: Neurology Authors: Teo, K. C., Mahboobani, N. R., Lee, R., Siu, D. C., Cheung, R., Ho, S. L., Lau, G. K., Chan, K. H. Tags: New Antithrombotic Agents for Stroke Prevention Poster Presentations Source Type: research

Direct Thrombin Inhibitors May Have A Decreased Risk Of Intracerebral Hemorrhage Compared With Older Anticoagulants (P5.140)
CONCLUSIONS: We found no significant difference in risk of ICH with DTI compared to the AC group and a trend towards lower risk with DTI. Future studies with larger numbers on DTIs are needed to confirm differences in ICH risk between DTIs and other anticoagulants.Disclosure: Dr. Ravipati has nothing to disclose. Dr. Woo has received research support from the National Institutes of Health. Dr. Sekar has received research support from the National Institutes of Health. Dr. Moomaw has received research support from the National Institutes of Health. Dr. Flaherty has received personal compensation for activities with CSL Behr...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Ravipati, S., Woo, D., Sekar, P., Moomaw, C., Flaherty, M., Osborne, J. Tags: Cerebrovascular Disease and Interventional Neurology: Intracerebral Hemorrhage and Other Hemorrhages Source Type: research

Use of Apixaban and Warfarin in Patients Undergoing Procedures: Insights from ARISTOTLE (I2-2.003)
CONCLUSIONS: Procedures are common in patients with atrial fibrillation. The majority of procedures are non-major and non-emergent, and anticoagulation therapy is likely to be stopped peri-procedure. Overall and among emergent procedures, rates of clinical events in the first 30 days post-procedure were low and comparable between treatment groups.Study Supported by: Bristol-Myers Squibb Company and Pfizer Inc. Editorial assistance (i.e., formatting the abstract to ensure compliance with AAN guidelines) was provided by Claire Hall of Caudex Medical and was funded by Bristol-Myers Squibb Company and Pfizer Inc.Disclosure: Dr...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Lopes, R., Garcia, D., Wojdyla, D., Dorian, P., Alexander, J., Wallentin, L., Lanas, F., Hanna, M., Held, C., Granger, C. Tags: New Antithrombotic Agents for Stroke Prevention Data Blitz Presentations Source Type: research

Direct Thrombin Inhibitors May Have A Decreased Risk Of Intracerebral Hemorrhage Compared With Older Anticoagulants (I2-2.005)
CONCLUSIONS: We found no significant difference in risk of ICH with DTI compared to the AC group and a trend towards lower risk with DTI. Future studies with larger numbers on DTIs are needed to confirm differences in ICH risk between DTIs and other anticoagulants.Disclosure: Dr. Ravipati has nothing to disclose. Dr. Woo has received research support from the National Institutes of Health. Dr. Sekar has received research support from the National Institutes of Health. Dr. Moomaw has received research support from the National Institutes of Health. Dr. Flaherty has received personal compensation for activities with CSL Behr...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Ravipati, S., Woo, D., Sekar, P., Moomaw, C., Flaherty, M., Osborne, J. Tags: New Antithrombotic Agents for Stroke Prevention Data Blitz Presentations Source Type: research

Systemic Inflammation Exacerbates Stroke in Patients with Left Ventricular Assist Device (P4.235)
CONCLUSIONS:In LVAD patients, total prevention of cerebrovascular complications cannot be accomplished only by adjusting warfarin dosage to meet the therapeutic range. However, recognition of increased CRP and appropriate management of inflammation prior to the stroke onset may enable us to avoid its aggravation and secure patient’s opportunity for heart transplantation.Disclosure: Dr. Ohtomo has nothing to disclose. Dr. Iwata has received personal compensation for activities with Janssen Pharmaceuticals, Eisai Inc., Daiichi Pharmaceutical Corp., Ono Pharmaceutical, and Takeda Pharmaceutical Co. Ltd. Dr. Iwata has re...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Ohtomo, R., Iwata, A., Kinoshita, O., Shimizu, J., Ono, M., Tsuji, S. Tags: Cerebrovascular Disease and Interventional Neurology: Cardiac Source Type: research

Thrombophilia in Young Patients with Cerebrovascular Disease. AISYF Study (S55.005)
Conclusion: Our study showed alterations in 17/125(14%) patients with arterial CVA, excluded PAI abnormalities.With the exception of antiphospholipid antibodies the value of testing TF as part of the evaluation of patients with arterial CVA, even in patients with a cryptogenic event,is still controversial and should not lead to anticoagulation of all these patients.Study Supported by Shire HGTDisclosure: Dr. Leon Cejas has nothing to disclose. Dr. Reisin has received personal compensation for activities with Shire Pharmaceuticals Group. Dr. Reisin has received personal compensation in an editorial capacity for Neurology. D...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Leon Cejas, L., Reisin, R. Tags: Pediatric Stroke and Stroke in the Young Source Type: research

Long-term survival after ischemic stroke in patients with atrial fibrillation
Conclusions: Ischemic stroke approximately triples the mortality rate in patients with atrial fibrillation. This effect persists well beyond the immediate period poststroke and is strongly associated with disability after stroke. Stroke prevention by anticoagulation has even greater beneficial effects on survival than usually considered when focusing solely on 30-day mortality rates.
Source: Neurology - March 24, 2014 Category: Neurology Authors: Fang, M. C., Go, A. S., Chang, Y., Borowsky, L. H., Pomernacki, N. K., Udaltsova, N., Singer, D. E. Tags: Outcome research, Stroke prevention, Cardiac, Cohort studies, Infarction ARTICLE Source Type: research

Summary of evidence-based guideline update: Prevention of stroke in nonvalvular atrial fibrillation: Report of the Guideline Development Subcommittee of the American Academy of Neurology
Objective: To update the 1998 American Academy of Neurology practice parameter on stroke prevention in nonvalvular atrial fibrillation (NVAF). How often do various technologies identify previously undetected NVAF? Which therapies reduce ischemic stroke risk with the least risk of hemorrhage, including intracranial hemorrhage? The complete guideline on which this summary is based is available as an online data supplement to this article. Methods: Systematic literature review; modified Delphi process recommendation formulation. Major conclusions: In patients with recent cryptogenic stroke, cardiac rhythm monitoring probabl...
Source: Neurology - February 24, 2014 Category: Neurology Authors: Culebras, A., Messe, S. R., Chaturvedi, S., Kase, C. S., Gronseth, G. Tags: All Cerebrovascular disease/Stroke SPECIAL ARTICLE Source Type: research